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A B S T R A C T
Objective: The aim of this study is to prospectively assess the diagnostic accuracy of pulmonary
embolism severity index, echocardiogram, computed tomography pulmonary angiogram (CTPA), and N-
terminal pro b-type natriuretic peptide (NT-proBNP) for predicting adverse events in acute pulmonary
embolism patients.
Methods: Thirty consecutive acute pulmonary embolism patients were included in this study. Combined
adverse events consisted of in-hospital death or use of escalation of care including cardiopulmonary
resuscitation, mechanical ventilation, vasopressor therapy, or secondary thrombolysis during hospital
stay.
Results: The outcomes were met in 30% of patients. Qanadli index (a measure of clot burden on CTPA)
and NT-proBNP were signiﬁcantly higher in patients with adverse events than those without
(p = 0.005 and p = 0.009, respectively). PESI had moderate positive correlation with right ventricular
dysfunction (RVD) (r = 0.449, p = 0.013) but there was no signiﬁcant difference in PESI between patients
with and without adverse events (p = 0.7). Receiver operating characteristic analysis indicated that
Qanadli index was the best predictor of adverse events with area under the curve (AUC) of 0.807 (95% CI:
0.651–0.963) with a negative predictive value (NPV) of 100% and positive predictive value (PPV) of 47.4%
at cut-off value of 19. Right ventricle to left ventricle ratio on CTPA was found to predict RVD with AUC of
0.94 (95% CI: 0.842–1.000), NPV (77.8%), and PPV (95.2%) at cut-off value at 1.15.
Conclusion: Qanadli index is more accurate predictor of adverse events than pulmonary embolism
severity index, NT-proBNP, and RVD on echocardiogram and CTPA.
 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contents lists available at ScienceDirect
Indian Heart Journal
jo u rn al h om epag e: ww w.els evier .c o m/lo cat e/ ih j1. Introduction
Acute pulmonary embolism (PE) presents with wide spectrum
and variable prognosis. Risk stratiﬁcation is of paramount
importance and is useful not only to select an appropriate
treatment strategy but also to potentially reduce costs of
management. Currently, bedside echocardiography is the principal
risk-stratifying tool by assessing right ventricular overload.1–3
Subset of patients with right ventricular dysfunction (RVD) who
are initially stable detoriate during hospital stay and require
escalation of care including thrombolysis. Identifying such patients
at admission may help to prioritize them to close monitoring in* Corresponding author at: Department of Cardiology, SVIMS, Tirupati 517507,
Andhra Pradesh, India. Tel.: +91 9849221650.
E-mail address: cardiologysvims@gmail.com (D. Rajasekhar).
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creativecommons.org/licenses/by-nc-nd/4.0/).intensive care unit, which may improve outcomes. Moreover there
are no established reference values to further stratify RVD patients
into mild, moderate, and severe by echocardiogram.4
The prognostic value of echocardiography in hemodynamically
stable patients appears moderate and is mostly due to the poor
standardization of echocardiographic criteria.5,6 Many factors
besides echocardiography have been shown to have prognostic
value in the short-term including biomarkers,7–11 as well as,
computed tomography pulmonary angiogram (CTPA).12,13 Recent
guidelines from both American and European societies recom-
mend risk stratiﬁcation be an integral part in the evaluation and
management of patients with acute PE.14,15 However, most
accurate predictor is controversial. These acute PE practice
guidelines emphasize the prognostic utility of clinical risk
prediction scores, biomarkers, and imaging studies but they do
not indicate which method is the preferred means of risk
stratiﬁcation. Clinical prognostic scores, echocardiography, CTPA,PESI, echocardiogram, CTPA, and NT-proBNP as risk stratiﬁcation
016), http://dx.doi.org/10.1016/j.ihj.2016.07.010
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in the same patient group. The aim of this study is to assess the
relationship and diagnostic accuracy of pulmonary embolism
severity index (PESI), echocardiography, CTPA, and N-terminal pro
b-type natriuretic peptide (NT-proBNP) with adverse events in
acute PE patients and to identify most accurate predictor.
2. Material and methods
2.1. Patients
We prospectively studied all consecutive patients with
conﬁrmed acute PE on CTPA and admitted in Sri Venkateswara
Institute of Medical Sciences (SVIMS), Tirupati between May
2013 and December 2014. Patients with renal impairment (serum
creatinine >1.5 mg/dl), preexisting left ventricular dysfunction
(LVEF < 50%) and preexisting chronic lung disorders which can
increase the after load to right ventricle were excluded. On
admission, patients were assessed for (1) detailed medical history
including clinical presentation and risk factors; (2) vital data
including respiratory rate, blood pressure, pulse rate, and pulse
oximetry oxygen saturation; (3) laboratory data including serum
creatinine, urea, sodium, potassium, and NT-proBNP; (4) echocar-
diogram and lower limb venous ultrasound; (5) electrocardiogram.
Adverse events were deﬁned as in-hospital death or use of
escalation of care, which included cardiopulmonary resuscitation,
mechanical ventilation, vasopressor therapy, or secondary throm-
bolysis during hospital stay. Thrombolysis at admission was
considered as primary thrombolysis and thrombolysis in patients
detoriated during hospital stay was considered as secondary
thrombolysis. Patients were stratiﬁed into ﬁve risk classes
according to PESI described by Aujesky et al.,16 which identiﬁed
11 features from demographic, history, and clinical ﬁndings. PESI
class I and II were considered as low-risk group and PESI class III,
IV, V were categorized as high-risk group.
2.2. Echocardiogram
Soon after the diagnosis of acute PE, Transthoracic echocardio-
gram was performed using a Philips IE-33 machine, Netherlands
with a 5–1 MHz frequency range transducer. Echocardiographic
RVD was deﬁned as presence of right ventricular dilation (right
ventricular end diastolic diameter [RVEDD] at the base >42 mm or
right ventricle to left ventricle end diastolic diameter ratio [RV/LV]
>1) or paradoxical ventricular septal motion or hypokinesia of
right ventricular free wall or tricuspid regurgitation jet velocity
(TRJV) > 2.8 m/s.4 RVEDD was deﬁned as maximal short-axis
dimension in the basal one third seen on right ventricle focused
apical four chamber view.4 Paradoxical ventricular septal motion
was visually assessed for ventricular septal curvature, looking for a
D shaped pattern in systole and diastole. TRJV was measured using
continuous-wave Doppler across tricuspid valve. All the echocar-
diograms were performed by a single qualiﬁed operator who was
blinded to clinical diagnosis, NT-proBNP and CTPA of the patients.
2.3. Computed tomography pulmonary angiography
CTPA was obtained from SIEMENS SOMATOM Deﬁnition AS, a
single source 128 slice CT scanner. Right ventricle diameter was
measured from inner wall to inner wall in the widest point, usually
seen in basal third of right ventricle, on transverse section of
reconstructed four chamber image showing the tricuspid valve at
its widest.17 So also left ventricular diameter measured when
mitral valve was at its widest.17 The RV/LV diameter ratio was
calculated. Ventricular septal bowing was subjectively judged as
being present or absent.Please cite this article in press as: Vamsidhar A, et al. Comparison of 
tools in patients with acute pulmonary embolism, Indian Heart J. (22.4. Qanadli index
Extent of pulmonary vascular obstruction was graded using
Qanadli index, a CTPA clot burden score, described by Qanadli
et al.18 A thrombus was considered non-occlusive if contrast
material was seen in the vessel adjacent to the ﬁlling defect. If
there was complete endoluminal ﬁlling of the vessel with
thrombus, non-perfusion of the distal vessel and attenuation of
distal segmental, and subsegmental branches in the occluded
vascular territory, it was considered as completely occlusive.
Following data was assessed, (1) location and number of ﬁlling
defects, (2) occlusive or non-occlusive nature of the ﬁlling defect.
Each lung was regarded as having 10 segmental arteries.
Subsegmental emboli were scored as a partial obstruction of the
segmental artery. PE involving a lobar or larger artery received a
score equal to number of segmental arteries supplied. Non-
occlusive PE was given a weight of 1 and occlusive PE was given a
weight of 2. The maximum obstruction score for each patient was
40 (20 for each lung).
All the CTPA were assessed by a single qualiﬁed radiologist who
was blinded to clinical data, echocardiogram and NT-proBNP levels
of the patient.
2.5. NT-proBNP
Within three hours of diagnosis of PE, NT-proBNP levels were
measured by using Roche CARDIAC proBNP test kit (code
04659449190, Roche Diagnostics Ltd., Germany) and Cobas h
232 POC (Point of Care) system.
The study design was observational and did not interfere with
therapeutic decisions. The protocol of this study was approved by
the Institutional ethics Committee. All participating patients gave
their informed consent.
3. Statistical analysis
Descriptive statistics including mean and standard deviation
(SD) for continuous variables and proportions for categorical data
were calculated. The differences observed were tested for
statistical signiﬁcance by unpaired student’s t-test, chi-square
test (parametric) and Mann–Whitney U test (non-parametric).
Correlations between continuous and categorical variables were
ascertained by using Pearson’s correlation tests respectively. A
p-value <0.05 was considered as statistically signiﬁcant. Receiver
operating characteristic (ROC) analysis was performed to ﬁnd out
sensitivity and speciﬁcity of the tests. All the statistical analysis
was performed on Microsoft-excel spread sheets and Statistical
Package for Social Sciences software (SPSS) for Microsoft Windows,
version 20.0, (IBM Corp., Armonk, NY, USA).
4. Results
A total of ﬁfty-six patients were screened for acute PE and
thirty-six were diagnosed to have acute PE. Six patients were
excluded as 4 patients had renal dysfunction, 1 had left ventricular
dysfunction and 1 had lung ﬁbrosis secondary to pulmonary
tuberculosis. Baseline characteristics of the study population are
displayed in Table 1. The patient’s age ranged from 21 to 76 years
with mean age of 41.20  12.98 years. Twenty four (80%) patients
were males and 6 (20%) were females. Dyspnea (100%) was the most
common symptom followed by chest pain (33.3%). Risk factors were
dyslipidemia (43.3%), smoking (30%), immobilization due to recent
trauma or surgery (26.7%), cancer (6.7%), hypertension (13.3%),
diabetes (10%), stroke (3.3.%), and coronary artery disease (6.7%).
Twenty-six patients (86.66%) had tachycardia. Two patients had
systemic hypotension at presentation. Fourteen patients (46.6%) hadPESI, echocardiogram, CTPA, and NT-proBNP as risk stratiﬁcation
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Table 1
Baseline characteristics of study population.
Characteristic Total cohort (n = 30) With AEs (n = 9) Without AEs (n = 21) p-value
Demographics
Age (years) 41.20  12.98 34.56  6.56 44.05  14.09 0.06
Male 24 (80%) 8 (88.9%) 16 (76.2%)
Female 6 (20%) 1 (11.1%) 5 (23.8%) 0.64
Chest pain 10 (33.3%) 1 (11.1%) 9 (42.9%) 0.20
Dyspnea
NYHA Class-1 1 (3.3%) 0 1 (4.8%)
NYHA Class-2 7 (23.3%) 0 7 (33.3%)
NYHA Class-3 13 (43.3%) 3 (33.3%) 10 (47.6%)
NYHA Class-4 9 (30.0%) 6 (66.7%) 3 (14.3%) 0.004*
Hemoptysis 05 (16.7%) 1 (11.1%) 4 (19%) 0.99
Syncope 6 (20%) 0 6 (28.6%) NA
Altered Sensorium 1 (3.3%) 1 (11.1%) 0 NA
Recent Surgery/trauma 8 (26.7%) 1 (11.1%) 7 (33.3%) 0.42
Cancer 2 (6.7%) 0 2 (9.5%) NA
Stroke 1 (3.3%) 0 1 (4.8%) NA
CAD 2 (6.7%) 0 2 (9.5%) NA
Dyslipidemia 13 (43.3%) 3 (33.3%) 10 (47.6%) 0.75
Smoking 9 (30%) 5 (55.6%) 4 (19%) 0.12
Hypertension 4 (13.3%) 0 4 (19%) NA
Diabetes 3 (10%) 0 3 (14.28%) NA
HR, bpm 118.50  15.65 121.0  13.49 117.19  16.62 0.55
SBP, mm of Hg 114.33  16.63 115.56  10.14 113.81  18.95 0.79
DBP, mm of Hg 73.20  9.30 73.33  5.0 73.14  10.74 0.96
Respiratory rate 29.33  5.91 31.22  4.24 28.52  6.42 0.26
Sr. Creatinine, mg/dl 1.08  0.24 1.16  0.21 1.05  0.24 0.24
Sr. Sodium, mg/dl 136.33  4.52 137.44  4.67 135.86  4.49 0.39
Sr. Potassium, mg/dl 4.07  0.71 3.82  0.76 4.17  0.67 0.22
ICU Stay, days 2.89  2.22 4.44  2.19 2.16  1.86 0.006*
AE, adverse events; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; SPO2, pulse oxymetry oxygen saturation; Sr., serum; TLT, thrombolytic therapy;
IQR, intra quartile range.
* Signiﬁcant p-value (p < 0.05).
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21 patients were diagnosed based on RV/LV ratio >1 (5 patients had
LVEDD < 42 mm and 16 had LVEDD > 42 mm) and 1 patient based on
right ventricle free wall hypokinesia and TRJV > 2.8 m/s. Seven
patients had hyponatremia (23.33%) and ﬁve patients had hypokale-
mia (16.66%). There was no statistically signiﬁcant difference in
serum urea, sodium, and potassium among patients with and without
adverse events as well as among patients with and without RVD. Nine
patients (30%) had deep vein thrombosis.
Ten patients (33.3%) were thrombolysed with streptokinase of
whom two patients were thrombolysed (primary thrombolysis) at
admission due to systemic hypotension. All patients were treated
with heparin. Nine patients had complicated in hospital course of
whom 2 patients (6.7%) died (Table 2). Eight patients (26.7%) were
thrombolysed (secondary thrombolysis) after deterioration during
hospital stay. There was need for mechanical ventilation in
2 patients (6.7%) and inotropic support in 2 patients (6.7%). All
these 9 patients had RVD.
Prognostic parameters of patients with and without adverse
events are displayed in Table 3.
4.1. Clinical prognostic scoring (PESI)
Patients in PESI class I, II, III, IV and V were 13.3%, 40%, 26.7%,
10%, and 10%, respectively. Fourteen patients were categorized asTable 2
Combined adverse events in study population.
Combined adverse events Total cohort (n = 30)
Secondary thrombolysis 8 (26.7%)
Mechanical ventilator 2 (6.7%)
Inotropes 2 (6.7%)
In-hospital deaths 2 (6.7%)
Please cite this article in press as: Vamsidhar A, et al. Comparison of 
tools in patients with acute pulmonary embolism, Indian Heart J. (2high risk according to PESI. Four patients in low-risk group (25%)
and 5 patients in high-risk group (39.28%) had adverse events
during hospital stay. Two patients, who were categorized at
admission as low risk, expired during hospital stay. There is no
signiﬁcant difference in PESI score between patients with and
without adverse events (p = 0.77).
4.2. Echocardiography
There was no statistically signiﬁcant difference of RV/LV ratio,
RVEDD, and TRJV, measured at admission, among patients with
and without adverse events (p = 0.38, p = 0.27, and p = 0.36,
respectively). There was no adverse event in patients without
RVD. ROC analysis of RVEDD and RV/LV ratio on echocardiography
in predicting adverse events is displayed in Table 4.
4.3. CTPA based parameters
Mean Qanadli index of whole cohort was 19.37  7.55. There was
a signiﬁcant difference in Qanadli index among patients with and
without adverse events (p = 0.005) as well as patients with and
without RVD (p = 0.001). There was no signiﬁcant difference in CTPA
RV/LV ratio among patients with and without adverse events (p = 0.27)
while there was statistically signiﬁcant difference in CTPA RV/LV ratio
among patients with and without RVD (p = 0.0001). Qanadli index
with a cut-off value of >19 discriminates patients with adverse events
with AUC of 0.807 (speciﬁcity: 52.38% and sensitivity: 100%).
4.4. NT-proBNP
Median NT-proBNP of patients was 2032 pg/ml. Patients with
adverse events had higher NT-proBNP levels than those without
(p = 0.0094). None of the patients with lower NT-proBNP (<729 pg/
ml) had adverse events. The ROC analysis (Fig. 1 and Table 4)PESI, echocardiogram, CTPA, and NT-proBNP as risk stratiﬁcation
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Table 3
Prognostic variables in patients with and without adverse events.
Characteristic Total cohort (n = 30) With AEs (n = 9) Without AEs (n = 21) p-value
PESI score 90.03  25.44 87.89  18.20 90.95  28.34 0.77
Echocardiographic parameters
Echo RV/LV ratio 1.05  0.16 1.07  0.09 1.02  0.16 0.38
RVEDD, mm 42.53  7.96 45.0  5.54 41.48  8.7 0.27
TR JV, m/s 2.77  1.07 3.08  0.87 2.73  0.98 0.36
Echo RV dysfunction
Yes 22 (73.3%) 09 (100%) 13 (61.9%) –
No 08 (26.7%) 00 (0%) 08 (38.1%)
Qanadli index 19.37  7.55 25.0  4.33 16.95  7.39 0.005*
CT RV/LV ratio 1.44  0.44 1.57  0.35 1.38  0.45 0.27
IVS bowing
Yes 17 (56.7%) 8 (88.9%) 9 (42.9%)
No 13 (43.3%) 1 (11.1%) 12 (57.1%) 0.04*
Median NTproBNP, pg/ml 2032.50 3451.0 1392.5 0.0094*
(IQR) (550.0–4082.0) (2425.0–6784.0) (315.0–2506.0)
AE, adverse events; echo, echocardiography; RVD, right ventricular dysfunction; TRJV, tricuspid regurgitation jet velocity; PAOI, pulmonary vascular obstruction index; RV,
right ventricle; LV, left ventricle.
* Signiﬁcant p-value (p < 0.05).
Table 4
ROC analysis of various prognostic tools in predicting adverse events.
Variable Cut-off AUC 95% CI p-value Sensitivity (%) Speciﬁcity (%) PPV NPV
Qanadli index >19 .807 0.651–0.963 0.009 100 52.38 47.4 100
NT-proBNP >729 .772 0.593–0.952 0.020 100 38.10 40.91 100
RV/LV ratio on echocardiogram >0.95 .709 0.525–0.893 0.074 100 42.86 42.9 100
CT RV/LV ratio >1.15 .646 0.446–0.845 0.213 100 42.9 42.9 100
RVEDD >47 .675 0.463–0.886 0.135 55.56 85.7 62.5 81.8
AUC, area under curve; PPV, positive predictive value; NPV, negative predictive value; NT-proBNP, N-terminal pro-brain natriuretic peptide; RV, right ventricle; LV, left
ventricle; CT, computed tomography; RVEDD, right ventricular end diastolic diameter.
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ments in discriminating patients with and without adverse events.
The AUC was 0.772, which indicates good discriminative power. A
NT-proBNP value > 729 pg/ml had a speciﬁcity rate of 38.1% and
positive predictive value of 40.91% for detecting adverse events.Fig. 1. Receiver operating characteristics of progno
Please cite this article in press as: Vamsidhar A, et al. Comparison of 
tools in patients with acute pulmonary embolism, Indian Heart J. (24.5. Right ventricular dysfunction
At admission, between patients with RVD and without RVD,
there was signiﬁcant difference in systolic blood pressure, diastolic
blood pressure, and arterial saturation but there was no signiﬁcantstic parameters in predicting adverse events.
PESI, echocardiogram, CTPA, and NT-proBNP as risk stratiﬁcation
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Table 5
Relationship between right ventricular dysfunction and other prognostic param-
eters.
Echocardiographic RVD vs. Correlation coefﬁcient p-value
SBP 0.412 0.024*
PESI score 0.449 0.013*
Qanadli index 0.694 <0.0001*
NT-proBNP 0.767 <0.0001*
CT RV/LV ratio 0.675 <0.0001*
SBP, systolic blood pressure; PESI, pulmonary embolism severity index; NT-proBNP,
N-terminal pro-brain natriuretic peptide; CT, computed tomography; RV, right
ventricle; LV, left ventricle.
* Signiﬁcant p-value (p < 0.05).
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higher serum creatinine levels than those without (1.15  0.23 mg/
dl vs. 0.089  0.13 mg/dl; p < 0.007). Nine patients in low-risk PESI
group (56.25%) and 13 patients in high-risk PESI group (92.85%) had
RVD. Majority of patients with RVD were in class II and III (16 patients,
72.8%). Majority of patients without RVD were in class I and II
(7 patients, 87.5%). There was signiﬁcant difference in PESI score in
patients with and without RVD (96.45  24.57 vs. 72.38  19.62;
p = 0.02). There is moderate positive correlation of PESI with RVD
(r = 0.449, p = 0.013). Correlation of prognostic parameters with RVD
is displayed in Table 5. On ROC analysis CTPA RV/LV ratio predicted
RVD with AUC of 0.94 (95% CI: 0.842–1.000) at cut-off value of >1.15
(sensitivity: 90%; speciﬁcity: 87.5%; negative predictive value: 77.8%;
positive predictive value: 95.2%). Qanadli index and CT RV/LV ratio
had good positive correlation with RVD (r = 0.694, p < 0.0001 and
r = 0.675, p < 0.0001, respectively). There was signiﬁcant difference
in median NT-pro BNP levels among patients with and without RVD
(2664.50 pg/ml vs. 300 pg/ml; p < 0.0001).
4.6. Intensive care unit stay
Mean intensive care unit (ICU) stay was 2.89  2.22 days.
Patients with RVD had signiﬁcantly prolonged ICU stay than those
without (mean ICU stay in days; 3.70  0.78 vs. 0.71  0.75,
p = 0.001). Patients with adverse events had signiﬁcantly prolonged
ICU stay than those without (mean ICU stay in days; 4.44  2.19 vs.
2.16  1.86, p = 0.006). Qanadli index, RVD, NT-proBNP and RV/LV
ratio on echocardiogram signiﬁcantly correlated with ICU stay
(r = 0.426, p = 0.024; r = 0.674, p < 0.0001; r = 0.615, p < 0.0001 and
r = 0.567, p = 0.002 respectively). RV/LV ratio on echocardiogram
correlated with ICU stay (r = 0.567 and p = 0.002) but RV/LV ratio on
CTPA did not correlate with ICU stay (r = 0.242, p = 0.215).
5. Discussion
In this prospective study we assessed the prognostic values of
Qanadli index, NT-pro BNP, PESI, and right ventricular dilation
parameters like RVEDD, RV/LV ratio on CTPA, and echocardiogram
in predicting adverse events. We found that in acute PE: (1) NT-
proBNP and Qanadli index have good discriminative power for the
detection of adverse events; (2) CTPA RV/LV ratio predicts RVD but
not adverse events; (3) there is no relationship between PESI and
adverse events; (4) Qanadli index is the most accurate predictor of
adverse events than NT-proBNP, PESI, RVEDD, and RV/LV ratio.
Acute pressure overload and failure of right ventricle is a critical
event in pathophysiology of acute PE. The diagnosis of RVD in acute
PE is of utmost importance because RVD is associated with
mortality.1,2,19,20 In our study all adverse events occurred in
patients with RVD and secondary thrombolysis was required only
in patients with RVD.1,2 All the patients without RVD had
uncomplicated hospital course similar to other studies.5,6 Unfor-
tunately, there is heterogeneity in deﬁnition of right ventricularPlease cite this article in press as: Vamsidhar A, et al. Comparison of 
tools in patients with acute pulmonary embolism, Indian Heart J. (2dilation by echocardiography in different studies as the criteria
was not well established.1,2,21,22 Therefore, we have taken
reference values from Guidelines for the echocardiographic
assessment of the right heart in adults by American Society of
Echocardiography.4 Following these standard guidelines in future
studies may help to maintain uniformity and may make analysis
easier. Echocardiography has several limitations like operator
dependence and limited acoustic window in obese and pulmonary
disease patients. Moreover, there are no standardized echocardio-
graphic reference values for further stratiﬁcation of RVD into mild,
moderate, and severe, signifying the need for other prognostic
indicators with incremental prognostic value for precise stratiﬁ-
cation. NT-proBNP, PESI, CTPA RV/LV ratio, and Qanadli index
correlated well with RVD and hence can be useful as prognostic
indicators for RVD. However, NT-proBNP and Qanadli index
provide indirect evidence of right ventricular dilation. Like
echocardiography, CTPA RV/LV ratio provides direct evidence of
right ventricular dilation.
On ROC analysis NT-proBNP had good sensitivity and negative
predictive value for patients without adverse events (100% and
100%) and modest speciﬁcity and positive predictive value for
those with adverse events (38.1% and 40.9% respectively). NT-
proBNP is an effective tool to identify those without adverse events
than those with adverse events. Our results corroborate with those
of other published studies that have demonstrated a lower rate of
in-hospital complications and better short-term prognosis in PE
patients with low NT-proBNP levels.21,23,11 In patients with low
NT-proBNP levels echocardiography will have no incremental
prognostic value because of good negative predictive value of NT-
proBNP for adverse events. Though various studies23,11,24 had
proposed different cut-off values for adverse events, all studies
have found that NT-proBNP had low speciﬁcity and high sensitivity
for adverse events. Discrepancies in cut-off value may be due to
differences in the characteristics of the patients included,
measurement at different stages of presentation and analysis of
different endpoints.
CTPA is the best imaging modality for diagnosis of acute PE and
its prognostic ability is less deﬁned. According to several
reports,12,13,25,26 CTPA RV/LV ratio is a strong predictor of mortality
while few27 reported that there is no association between the RV/
LV ratio and death. We found that CTPA RV/LV ratio does not has
the ability to predict occurrence of adverse events (p = 0.213).
Some reported that CTPA RV/LV ratio had good sensitivity and
speciﬁcity for detecting RVD.28–30 Few studies have assessed RVD
qualitatively on CTPA11,30 while Mansencal et al.28 quantiﬁed RVD
by CTPA RV/LV ratio and compared with echocardiography. In this
study we found that CTPA RV/LV ratio has good correlation with
RVD (r = 0.675) and is able to predict RVD with good discriminative
power (AUC = 0.94).
Qanadli index on CTPA provides objective, reproducible and
quantiﬁable assessment of pulmonary arterial obstruction.18,31 Its
role in risk stratiﬁcation in these patients is debated. We found that
Qanadli index is greater in patients with adverse events and RVD.
Qanadli index predicts patients at low risk of adverse events with
good negative predictive value but positive predictive value for
adverse events is modest. Contrary to our ﬁndings some
studies29,30,32,33 did not ﬁnd any signiﬁcant association between
the pulmonary artery embolic burden assessed with the Qanadli
index and short-term death due to PE. Apfaltrer et al.34 evaluated
50 patients and reported that pulmonary artery obstruction scores
can differentiate between patients with and without RVD but not
correlated with adverse clinical outcome. Our study results are
consistent with some other studies,12,35,36 which reported that
Qanadli index is a signiﬁcant predictor of short-term outcomes. Few
other studies37 used Mastora score for assessing pulmonary artery
embolic burden and found that it will predict adverse events.PESI, echocardiogram, CTPA, and NT-proBNP as risk stratiﬁcation
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Apfaltrer et al.34 and Araoz et al.17 respectively while in our study it
was 19.37. Mean age was around 60 years in studies by Ghaye
et al.26 and Araoz et al.17 while in our study it was
41.20  12.08 years. These differences in age and severity of
pulmonary obstruction reﬂect differences in the patient character-
istics among various studies. Moreover we have not addressed inter
and intra observer variability. The outcomes studied in various
reports were different. Most of the studies did not exclude pulmonary
co-morbidities which can inﬂuence outcomes. In patients with
associated pulmonary disease, less pulmonary vascular obstruction is
required to achieve a similar degree of physiologic impairment.38
Discordance among studies regarding embolic burden may be due to
difference in patient’s characteristics and deﬁnition of outcomes.
Analysis of the accuracy of CTPA parameters in detecting adverse
events is limited by heterogeneity across studies. This highlights the
need for large prospective multicentre study to evaluate the
prognostic role of CTPA parameters.
We found that Qanadli index is better predictor of adverse
events than NT-proBNP and RVEDD, RV/LV ratio on echocardio-
gram and CTPA as indicated by greater AUC. Qanadli index has
more speciﬁcity and positive predictive value than NT-proBNP in
identifying adverse events but not sufﬁcient high enough to be
used alone. Qanadli index and NT-proBNP have good sensitivity
and negative predictive value but have poor speciﬁcity and
positive predictive values. Hence, both tests identify patients with
benign in-hospital course who may require abbreviated hospital
stay. The lack of consistent ﬁndings from various studies currently
limits the ability to assess prognosis by CTPA measurements alone
in those with acute PE. Biomarkers like NT-proBNP because of their
wide availability irrespective of location or time of the day and
non-invasive nature seems to be appropriate to be used along with
CTPA for risk assessment.
The results of this study may have important clinical implica-
tions. Qanadli index and NT-proBNP are better predictors of
adverse events than echocardiography. A simple and rapid bedside
measurement of NT-pro-BNP might facilitate triage of acute PE
patients. As CT is best diagnostic imaging modality and simulta-
neous assessment of the cardiac chambers is a quick and practical
means of evaluating for right heart dysfunction. CTPA can be useful
as both diagnostic and prognostic tool in patients. Qanadli index
and NT-proBNP will help to identify subset of acute PE patients
with RV dysfunction, who are hemodynamically stable at
admission, worsens during hospital stay even after initiation of
anticoagulation. Identiﬁcation of this sub group shall help in early
recognition, close monitoring, and lower threshold for intensive
therapy, which may improve outcomes.
6. Limitations
The main limitation of the study is small sample size. This study
was conducted at single centre without follow up of the patients
after discharge. The role of prognostic tools in prediction of long-
term complications and quality of life needs to be evaluated. We
used non-ECG gated computed tomography which has limitations
in accurately measuring ventricular chamber size. Inter- and intra-
observer variability in assessing computed tomography parame-
ters were not studied. The prognostic value of combined prognostic
parameters was not assessed which needs to be considered in
future research.
7. Conclusion
Qanadli index is a better prognostic indicator than NT-proBNP,
PESI, RVEDD, and RV/LV ratio on CTPA and echocardiogram in acutePlease cite this article in press as: Vamsidhar A, et al. Comparison of 
tools in patients with acute pulmonary embolism, Indian Heart J. (2pulmonary embolism patients. RV/LV ratio on CTPA is adequate for
predicting right ventricular dysfunction.
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